The Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment (PRT) has received the European CE Mark approval, Sorin Group has announced.
The PRT component of the valve is aimed at relieving calcification of the device and increase its durability. A released statement by Sorin said that phospholipids play a key role in the calcification process of biosprotheses.
Advertisement"The addition of PRT to the Mitroflow bioprosthesis will help mitigate potential calcification and possibly further improve the tissue valve's clinically proven outstanding durability," it added.
You May Also Like